Additionally, in a multicentric real‐life analysis, a Karnofsky performance score (KPS) ≥ 90% emerged to be an independent prognostic factor for progression‐free and overall survival (PFS and OS) for the treatment with combined temozolomide and CCNU in newly diagnosed MGMT promoter methylated glioblastoma [4]. The gene discussed is MGMT; the disease is glioblastoma.